AI Article Synopsis

  • The study examines the risks of complications following major lung surgery after neoadjuvant concurrent chemoradiation therapy in patients with stage IIIA-N2 non-small cell lung cancer.
  • It reveals that patients over 70 years old, those with low body mass index, and those undergoing pneumonectomy face significantly higher rates of morbidity and mortality post-surgery.
  • The findings suggest that alternative treatments may be more suitable for high-risk patients, particularly the elderly or those with poorer lung function, rather than pursuing surgical options.

Article Abstract

Background: Major pulmonary resection after neoadjuvant concurrent chemoradiation therapy (nCCRT) is associated with a substantial risk of postoperative complications. This study investigated postoperative complications and associated risk factors to facilitate the selection of suitable surgical candidates following nCCRT in stage IIIA-N2 non-small cell lung cancer (NSCLC).

Methods: We conducted a retrospective analysis of patients diagnosed with clinical stage IIIA-N2 NSCLC who underwent surgical resection following nCCRT between 1997 and 2013. Perioperative characteristics and clinical factors associated with morbidity and mortality were analyzed using univariable and multivariable logistic regression.

Results: A total of 574 patients underwent major lung resection after induction CCRT. Thirty-day and 90-day postoperative mortality occurred in 8 patients (1.4%) and 41 patients (7.1%), respectively. Acute respiratory distress syndrome (n=6, 4.5%) was the primary cause of in-hospital mortality. Morbidity occurred in 199 patients (34.7%). Multivariable analysis identified significant predictors of morbidity, including patient age exceeding 70 years (odds ratio [OR], 1.8; p=0.04), low body mass index (OR, 2.6; p=0.02), and pneumonectomy (OR, 1.8; p=0.03). Patient age over 70 years (OR, 1.8; p=0.02) and pneumonectomy (OR, 3.26; p<0.01) were independent predictors of mortality in the multivariable analysis.

Conclusion: In conclusion, the surgical outcomes following nCCRT are less favorable for individuals aged over 70 years or those undergoing pneumonectomy. Special attention is warranted for these patients due to their heightened risks of respiratory complications. In high-risk patients, such as elderly patients with decreased lung function, alternative treatment options like definitive CCRT should be considered instead of surgical resection.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11240090PMC
http://dx.doi.org/10.5090/jcs.23.165DOI Listing

Publication Analysis

Top Keywords

stage iiia-n2
12
iiia-n2 non-small
8
non-small cell
8
cell lung
8
lung cancer
8
concurrent chemoradiation
8
chemoradiation therapy
8
postoperative complications
8
patient age
8
p=002 pneumonectomy
8

Similar Publications

Objective: To explore the impact of neoadjuvant immunotherapy on the clinical efficacy of stage IIIA-N2 non-small cell lung cancer (NSCLC) patients.

Methods: The retrospective study was conducted on 120 patients with stage IIIA-N2 NSCLC admitted to our hospital during April 2020 to April 2022. The control group received local chemotherapy, while the combination group received neoadjuvant immunotherapy on the basis of chemotherapy.

View Article and Find Full Text PDF

Objectives: There is limited consensus on resectability criteria for Stage IIIA-N2 non-small cell lung cancer (NSCLC). We examined the patient characteristics, N2 status, treatment decisions, and clinical outcomes according to the treatment modality for Stage IIIA-N2 NSCLC in Japan.

Materials And Methods: Patients with Stage IIIA-N2 NSCLC in Japan were consecutively registered in the SOLUTION study between 2013 and 2014.

View Article and Find Full Text PDF

Background And Purpose: We aimed to assess the benefits of postoperative radiotherapy (PORT) in completely resected patients with pathologic stage IIIA(N2) non-small cell lung cancer (NSCLC) with a high risk of locoregional recurrence (LRR).

Materials And Methods: A prospective, randomized trial was conducted starting in July 2016 to explore the optimal timing of PORT in high-LRR-risk patients with completely resected IIIA(N2) NSCLC (NCT02974426). Patients were identified as high-LRR-risk patients via the prognostic index (PI) model and were randomly assigned to PORT-first or PORT-last treatment.

View Article and Find Full Text PDF

Trimodal therapy and surgical approaches in stage IIIA/N2 non-small cell lung cancer.

Sci Rep

November 2024

Division of Thoracic Surgery, Department of Surgery, Changhua Christian Hospital, No. 135, Nanxiao St, Changhua City, Changhua County 500, Taiwan.

The standard treatment guideline for stage IIIA/N2 non-small cell lung cancer (NSCLC) remains controversial despite years of research, and the necessity of surgery is still debated. This study aims to explore optimal treatment and surgical methods for stage IIIA/N2 NSCLC patients.We obtained data from the Taiwan Cancer Registry (TCR) to compare the overall survival rates of different subgroups of stage IIIA/N2 NSCLC patients, as well as the overall survival rates of different treatment strategies and surgical methods.

View Article and Find Full Text PDF
Article Synopsis
  • This study examines the use of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for restaging non-small cell lung cancer (NSCLC) after initial treatment, validated by a separate procedure called video-assisted mediastinoscopic lymphadenectomy (VAMLA).* -
  • A retrospective analysis of patients showed that EBUS-TBNA has a moderate sensitivity (63.1%) but excellent specificity (100%) for identifying mediastinal disease, while VAMLA confirmed a 100% accuracy when follow-up was needed after a negative EBUS-TBNA result.* -
  • The findings suggest EBUS-TBNA should be the first choice for invasive rest
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!